RxDoctor Payments Data

David Tellalian, MD

Internal Medicine · Los Angeles, CANPI 1003073826

Payments from drug & device makers

$8,505in general payments, 2019–2025

Across 430 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$5K
  • Gilead$2K
  • Johnson & Johnson$479
  • Merck$241
  • Napo Pharmaceuticals Inc$171
  • Theratechnologies Inc.$170
  • plus $874 from 10 others

What the payments were for

  • Speaking & faculty fees$1001%
  • Food & beverage$8,35998%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,505 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$29,723
Medicare patients
158
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala177$779,013
SerostimSomatropin24$403,917
DovatoDolutegravir Sodium/Lamivudine43$127,021
DescovyEmtricitabine/Tenofov Alafenam44$112,897
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf22$104,673
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$58,575
TivicayDolutegravir Sodium20$52,690
PifeltroDoravirine19$35,774
MytesiCrofelemer12$28,266
OzempicSemaglutide23$21,650
XyostedTestosterone Enanthate27$15,131
EliquisApixaban12$6,945
Testosterone40$6,590
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,604
Testosterone Cypionate40$1,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,824$891,910221 claims
EMD Serono, Inc.Serostim$100$403,91724 claims
Viiv Healthcare CompanyDovato, Tivicay$4,745$179,71163 claims
MerckPifeltro$241$35,77419 claims
Napo Pharmaceuticals IncMytesi$171$28,26612 claims
Novo NordiskOzempic$143$21,65023 claims
Antares Pharma, Inc.Xyosted$123$15,13127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →